Cardiome Pharma Corp.'s (Vancouver,...

Cardiome Pharma Corp.'s (Vancouver, BC Canada) atrial fibrillation unsalable article RSD1235, met both primary and secondary endpoints in a Phase 2 clinical research The randomized, placebo-controlled, double-blind, step-dose trial included 56 bring under rules with a diagnosis of atrial fibrillation of duration greater than three hours and les than 72 hours. exposes were randomized to receive placebo or the research drug at a soft dose or high dose. The primary endpoint was the ability of the subject of attention drug to terminate atrial fibrillation within 30 minutes of infusion. Secondary endpoints

Phone Cards , Buy Zyban Online , Laptop Parts